Tiziana Life Sciences Announces Purchase of Common Shares by Executive Chairman

Rhea-AI Summary

Tiziana Life Sciences (Nasdaq: TLSA) announced on June 10, 2022, that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 50,000 common shares at $0.88 each. This acquisition increased Cerrone's stake from 37.60% to 37.64%. Tiziana specializes in developing innovative immunotherapy delivery methods, focusing on alternative routes such as nasal, oral, and inhalation. Their leading candidates include intranasal foralumab and milciclib, both of which have shown favorable safety profiles in clinical studies.

Positive

• Executive Chairman Gabriele Cerrone increased his shareholding from 37.60% to 37.64%
• Tiziana is developing novel drug delivery methods for immunotherapy, potentially improving efficacy and safety.
• Lead candidates have shown favorable safety profiles and clinical response in past studies.

Negative

• None.

NEW YORK, June 10, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes of drug delivery, today announces that it has been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 50,000 common shares at $0.88 per share.

The acquisition takes Mr Cerrone's interests from 37.60% to 37.64%.

About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal, oral and inhalation approaches in development have the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s two lead candidates, intranasal foralumab, the only fully human anti-CD3 mAb, and milciclib, a pan-CDK inhibitor, have both demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For further inquiries:

Tiziana Life Sciences Ltd Hana Malik, Business Development, and Investor Relations Manager   +44 (0) 207 495 2379 email: info@tizianalifesciences.com
Investors: Irina Koffler LifeSci Advisors, LLC 646.970.4681 ikoffler@lifesciadvisors.com

 

FAQ

What recent share acquisition did Tiziana Life Sciences (TLSA) announce?

On June 10, 2022, Tiziana Life Sciences announced that Panetta Partners Limited purchased 50,000 common shares at $0.88 each.

Who increased their stake in Tiziana Life Sciences (TLSA)?

Gabriele Cerrone, the Executive Chairman, increased his beneficial interest from 37.60% to 37.64%.

What is the focus of Tiziana Life Sciences (TLSA)?

Tiziana Life Sciences specializes in breakthrough immunotherapy delivery methods, particularly through nasal, oral, and inhalation routes.

What are Tiziana's lead candidates?

Tiziana's lead candidates include intranasal foralumab and milciclib, both of which have demonstrated favorable safety profiles.